The mission of the Chinese Society is to serve the traditional Chinese medicine sector, to safeguard the legitimate right of the members of the Society, to promote standardization and development, to propagate the culture of Chinese medicine, and to better satisfy medicinal needs.

"With 30,000 points of sale in China and 3,000 in the United States, we expect to see a significant boost in the sales of our over-the-counter natural and health supplements and related products," stated ONE's CEO Marius Silvasan. "The agreement with the Chinese Society is a key part of our aggressive push to increase distribution for our products in China and abroad. Through the Chinese Society our products will soon be available in the US, a key market for future growth," added Silvasan.

"The launch of our first CoQ10 concentrated beauty treatment which includes facial whitening, body slimming, and antioxidants has received positive feedback from the Chinese Society as well as the marketplace," stated Green Planet's CEO Min Zhao. "Our R&D team is working hard to develop new over-the-counter natural and health supplements and beauty products. As new products are developed we intend to work with the Chinese Society for their commercialization," added Mr. Zhao.

About ONE Bio, Corp.

ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

About Green Planet Bioengineering, Co., Ltd.

Green Planet Bioengineering CO., LTD. ("Green Planet") (http://www.greenplanetbio.com) (OTCBB: GPLB), a subsidiary of ONE Bio, Corp. (OTCBB: ONBI), is a high-tech bioengineering enterprise that engages in research & development, production and sale of various extracts from tobacco leaves residues destined for health supplements and organic agricultural products. Green Planet is headquartered in Miami, FL with its main operation located in Sanming and Fuzhou, China. Since founded in 2005, Green Planet offers a full range of high quality bio-ecological products which include raw chemical materials such as CoQ10 and Solanesol, organic fertilizers and pesticides and organic health nutrients and supplements. Company's unique position in the bioengineering industry comes from its R&D using patented cutting-edge methods to create abundant downstream products ranging from plant indigenous medicine, pharmaceutical intermediates to a long list of eco-friendly products.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.